Does Medicare Cover Ozempic? The Short Answer
Yes, but only for type 2 diabetes. Medicare Part D covers Ozempic (semaglutide) when prescribed to manage blood sugar in adults with type 2 diabetes. Medicare does not cover Ozempic for weight loss alone. This distinction matters because the same medication is increasingly prescribed off-label for weight management, and many beneficiaries are surprised when their claim is denied.
“The number one question I’m getting from clients in 2026 is about Ozempic and weight loss coverage,” says Karl Bruns-Kyler, founder of The Big 65 and a licensed Medicare advisor with over 20 years of experience. “The rules are complicated, and the landscape is changing fast. But as of right now, the diagnosis your doctor writes on the prescription determines everything.”
Federal law, specifically the Medicare Modernization Act of 2003, prohibits Medicare Part D from covering drugs prescribed solely for weight loss or weight gain. This statutory exclusion has been in place since the Part D program launched in 2006, and it applies to all GLP-1 receptor agonist medications when used for obesity treatment alone.
However, 2026 brings major changes. A new CMS demonstration program called the Medicare GLP-1 Bridge will provide limited weight-loss drug coverage starting July 2026. Below, we break down exactly what Medicare covers, what it does not, and what is changing.
What Medicare Part D Covers for Ozempic in 2026
Ozempic is FDA-approved for improving blood sugar control in adults with type 2 diabetes. When your doctor prescribes Ozempic for this indication, Medicare Part D plans may cover it.
Here is what you need to know about Part D coverage for Ozempic:
- Formulary placement: Ozempic is typically placed on a specialty or non-preferred brand tier. Each Part D plan has its own formulary (drug list), so coverage and tier placement vary by plan.
- Prior authorization: Most plans require prior authorization. Your doctor must submit documentation confirming a type 2 diabetes diagnosis.
- Step therapy: Some plans require you to try less expensive diabetes medications first (such as metformin or other GLP-1 drugs) before approving Ozempic.
- 2026 costs: The list price for Ozempic is approximately $935 per month (per pen). With Part D coverage, you will pay your plan’s deductible (up to $615 in 2026), then typically 25% coinsurance until you reach the annual out-of-pocket cap.
The $2,100 Out-of-Pocket Cap
Thanks to the Inflation Reduction Act, Medicare Part D now caps annual out-of-pocket drug spending at $2,100 in 2026 (up from $2,000 in 2025). Once you reach this limit, you pay $0 for all covered Part D drugs for the rest of the year. This is a transformative protection for beneficiaries taking expensive medications like Ozempic.
For someone taking Ozempic for diabetes, you would likely hit the $2,100 cap within the first two to three months of the year. After that, your Ozempic (and all other covered Part D prescriptions) cost nothing for the remainder of 2026.
You can also enroll in the Medicare Prescription Payment Plan, which spreads your out-of-pocket Part D costs into smaller monthly payments throughout the year rather than facing large bills upfront. Learn more about Part D costs in our Medicare Part D Plans 2026 Guide.
What Medicare Does NOT Cover: Weight Loss Prescriptions
This is the critical distinction. If your doctor prescribes Ozempic (or any GLP-1 medication) specifically for weight loss without a qualifying medical condition, Medicare Part D will not cover it.
The statutory exclusion in federal law prohibits Part D plans from covering “agents when used for anorexia, weight loss, and weight gain.” This exclusion applies regardless of:
- How effective the medication is for weight loss
- Whether your doctor believes it is medically necessary
- Your BMI or obesity-related health conditions
- Whether the drug is FDA-approved for weight management (under a different brand name)
“This is not a loophole that plans are choosing not to fill,” explains Bruns-Kyler. “It is a legal barrier built into the Medicare program. Plans are prohibited from covering weight-loss-only prescriptions, even if they wanted to.”
Medicare Coverage for Wegovy in 2026
Wegovy is the higher-dose version of the same active ingredient in Ozempic (semaglutide), but it is FDA-approved for different uses. Here is how Medicare covers Wegovy:
Covered: Cardiovascular Risk Reduction
In March 2024, the FDA approved Wegovy to reduce the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in adults with established cardiovascular disease who are also obese or overweight. Based on this approval, CMS confirmed that Medicare Part D plans can cover Wegovy for this specific cardiovascular indication.
To get Wegovy covered under Part D for cardiovascular risk reduction, you typically need:
- A documented diagnosis of established cardiovascular disease
- A BMI of 27 or higher (overweight or obese)
- Prior authorization from your Part D plan
- A prescription specifically for reducing cardiovascular risk (not weight loss)
Not Covered: Weight Loss Alone
Wegovy’s original FDA approval (2021) was for chronic weight management. For this indication, the same statutory exclusion applies: Medicare Part D cannot cover it. The drug, the dose, and even the results may be identical, but the diagnosis code on the prescription determines coverage.
Coming in July 2026: The Medicare GLP-1 Bridge
This is changing. Starting July 1, 2026, the new Medicare GLP-1 Bridge demonstration program will cover Wegovy for weight loss at a $50 per month copay. See the full details in the section below.
Medicare Coverage for Mounjaro and Zepbound
Mounjaro and Zepbound both contain tirzepatide, a dual GLP-1/GIP receptor agonist made by Eli Lilly. They are marketed under different brand names for different indications:
| Medication | Active Ingredient | FDA-Approved For | Medicare Part D Coverage |
|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes | Covered for diabetes |
| Wegovy | Semaglutide (higher dose) | Weight management; CV risk reduction | Covered for CV risk reduction only |
| Mounjaro | Tirzepatide | Type 2 diabetes | Covered for diabetes |
| Zepbound | Tirzepatide | Weight management; obstructive sleep apnea | Covered for OSA only |
| Rybelsus | Semaglutide (oral) | Type 2 diabetes | Covered for diabetes |
Key takeaway: The same molecule can be covered or denied based entirely on the diagnosis. Tirzepatide prescribed as Mounjaro for diabetes is coverable; the same molecule prescribed as Zepbound for weight loss is not. The critical factor is always the FDA-approved indication your doctor documents.
Zepbound for Obstructive Sleep Apnea
In December 2024, the FDA approved Zepbound for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Because OSA is a covered medical condition (not weight loss), Medicare Part D plans may cover Zepbound for this specific use. This has become a pathway for some beneficiaries who have both obesity and OSA to access tirzepatide through Medicare.
The Medicare GLP-1 Bridge: Weight Loss Coverage Starting July 2026
This is the biggest development in Medicare drug coverage in years. On December 23, 2025, CMS announced two programs that will, for the first time, provide Medicare coverage of GLP-1 drugs specifically for weight loss:
Medicare GLP-1 Bridge (July 1 to December 31, 2026)
The Medicare GLP-1 Bridge is a short-term demonstration program that provides early access to weight-loss GLP-1 drugs for eligible Medicare Part D beneficiaries. Here are the key details, directly from CMS:
- Eligible drugs: Wegovy (injection and tablets) and Zepbound
- Cost to beneficiaries: $50 per monthly supply (manufacturers provide drugs at a net price of $245 per monthly supply)
- Duration: July 1, 2026, through December 31, 2026
- How it works: The program operates outside the standard Part D benefit. CMS uses a central processor for prior authorization, claims, and pharmacy payment. Your Part D plan does not need to opt in.
- Available nationwide: All states and territories
Who Qualifies for the Medicare GLP-1 Bridge?
To be eligible, you must:
- Be enrolled in a Medicare Part D plan (standalone PDP or Medicare Advantage with drug coverage)
- Have a BMI of 35 or higher, OR a BMI of 27 or higher with at least one of the following: pre-diabetes, hypertension, dyslipidemia, or cardiovascular disease
- Have a provider submit a prior authorization request and prescription
- Not be using the same drug for a condition already coverable under standard Part D (for example, if you use Wegovy for cardiovascular risk reduction through your Part D plan, you cannot also get it through the Bridge for weight loss)
Important Limitations
There are a few things to be aware of:
- The $50 copay does not count toward your Part D deductible or $2,100 out-of-pocket cap (since the Bridge operates outside Part D)
- Low-income subsidy (Extra Help) benefits do not apply to Bridge prescriptions
- Beneficiaries in Special Needs Plans (SNPs), employer/union group waiver plans, and the Limited Income Newly Eligible Transition (LI NET) program are not eligible
The BALANCE Model: Full Coverage Starting January 2027
The Bridge program transitions into the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) starting January 1, 2027. Under BALANCE, participating Part D plans will be able to cover GLP-1 drugs for weight management as part of the standard Part D benefit, at prices negotiated between CMS and manufacturers.
This is a voluntary program for Part D plan sponsors, so coverage will depend on whether your plan participates. CMS is aiming for broad plan participation but has not yet confirmed which plans will join.
How to Check if Your Part D Plan Covers Ozempic
Whether you take Ozempic for diabetes or are exploring other GLP-1 options, here is how to verify your coverage:
- Check your plan’s formulary: Visit Medicare.gov Plan Compare and search for your specific plan. Every plan’s formulary is listed there.
- Call your plan directly: The member services number is on your Part D insurance card. Ask specifically whether Ozempic is covered, which tier it is on, and whether prior authorization is required.
- Ask your doctor: Your prescriber’s office can often check coverage through their electronic prescribing system and submit prior authorization if needed.
- Review during Annual Enrollment: Plans change their formularies every year. During the Annual Enrollment Period (October 15 to December 7), compare plans to find one that covers your medications at the best cost.
For a deeper look at how to choose the right plan, read our complete Part D guide.
Medicare Advantage and GLP-1 Drug Coverage
Medicare Advantage (Part C) plans that include prescription drug coverage (MA-PDs) follow the same Part D rules. They cannot cover weight-loss-only prescriptions due to the same statutory exclusion. However, Medicare Advantage plans may offer some additional benefits:
- Supplemental benefits: Some MA plans include supplemental health benefits like fitness programs, nutritional counseling, or wellness programs that can support weight management alongside medication.
- Lower out-of-pocket maximums: MA plans have an annual cap on total medical spending (separate from the Part D drug cap), which provides broader financial protection.
- Formulary differences: MA-PD plans create their own formularies within CMS guidelines. Some plans may offer better tier placement or lower copays for GLP-1 drugs used for covered conditions.
All MA-PD plans are also eligible for the Medicare GLP-1 Bridge starting July 2026. To compare plans in your area, see our guide on Medicare Advantage vs. Medigap.
Costs: What You Will Pay for GLP-1 Drugs With Medicare
Here is a realistic cost breakdown for GLP-1 medications under different Medicare scenarios in 2026:
| Scenario | Monthly Cost | Annual Cost (Estimate) | Notes |
|---|---|---|---|
| Ozempic with Part D (diabetes) | $250-$400 initially, then $0 | Up to $2,100 total | You hit the OOP cap in 2-3 months, then $0 rest of year |
| Wegovy with Part D (CV risk) | $250-$400 initially, then $0 | Up to $2,100 total | Same OOP cap applies for covered indication |
| GLP-1 Bridge (weight loss, July 2026) | $50 flat | $300 (6 months) | Does NOT count toward Part D OOP cap |
| Without coverage (out of pocket) | $935-$1,350 | $11,220-$16,200 | List price varies by drug and dose |
“The $2,100 cap is the most important number for anyone on an expensive medication,” notes Bruns-Kyler. “It means your total out-of-pocket drug costs for the entire year have a ceiling. Before the Inflation Reduction Act, there was no limit, and some of my clients were paying $5,000 to $10,000 a year on prescriptions.”
For a complete breakdown of all Medicare costs, visit our How Much Does Medicare Cost in 2026 guide.
Alternatives if Medicare Does Not Cover Your Weight Loss Medication
If you are not eligible for GLP-1 coverage through Medicare, here are some options to explore:
- Wait for the Medicare GLP-1 Bridge (July 2026): If you meet the BMI and clinical criteria, this program offers Wegovy or Zepbound at $50 per month.
- Talk to your doctor about covered indications: If you have type 2 diabetes, cardiovascular disease, or obstructive sleep apnea in addition to obesity, your doctor may be able to prescribe a GLP-1 for a covered condition.
- Manufacturer savings programs: Eli Lilly offers Zepbound through LillyDirect at reduced self-pay prices ($299-$449 per month). Note that Medicare beneficiaries cannot use manufacturer copay cards, but direct self-pay programs may be available.
- Compare Part D plans during AEP: Different plans have different formularies and cost-sharing. Shopping during the Annual Enrollment Period (October 15 to December 7) can help you find a plan that covers your specific medications at the lowest cost.
- Extra Help (Low-Income Subsidy): If your income and resources are limited, the Extra Help program can significantly reduce your Part D costs for covered drugs.
- Patient assistance programs: Both Novo Nordisk and Eli Lilly offer patient assistance programs for qualifying individuals who cannot afford their medications.
Frequently Asked Questions
Does Medicare cover Ozempic for weight loss?
No. Medicare Part D covers Ozempic only when prescribed for type 2 diabetes. Federal law prohibits Part D plans from covering drugs prescribed solely for weight loss. However, starting July 2026, the Medicare GLP-1 Bridge program will offer coverage of certain GLP-1 drugs (Wegovy and Zepbound, not Ozempic) for weight loss at a $50 monthly copay for eligible beneficiaries.
Does Medicare cover Wegovy?
Medicare Part D may cover Wegovy when prescribed for cardiovascular risk reduction in adults with established heart disease who are overweight or obese. It is not covered for weight loss alone under standard Part D. Starting July 2026, eligible beneficiaries can access Wegovy for weight loss through the Medicare GLP-1 Bridge program at $50 per month.
How much does Ozempic cost with Medicare Part D?
With Part D coverage for diabetes, you will pay your plan’s deductible (up to $615 in 2026) plus coinsurance (typically 25%) until you reach the $2,100 annual out-of-pocket cap. After reaching the cap, you pay $0 for all covered Part D drugs for the rest of the year. Most beneficiaries taking Ozempic reach this cap within two to three months.
What is the Medicare GLP-1 Bridge program?
The Medicare GLP-1 Bridge is a CMS demonstration program running from July 1 to December 31, 2026, that provides Medicare Part D beneficiaries access to Wegovy and Zepbound for weight loss at $50 per month. It operates outside the standard Part D benefit and requires prior authorization and BMI-based eligibility criteria.
Will Medicare cover weight loss drugs in 2027?
CMS plans to launch the BALANCE Model in January 2027, which would allow participating Part D plans to cover GLP-1 drugs for weight management as part of the standard Part D benefit. Coverage will depend on whether your specific plan participates. Additionally, Ozempic, Rybelsus, and Wegovy are selected drugs for the Medicare Drug Price Negotiation Program, with negotiated lower prices taking effect in 2027.
Can my doctor prescribe Ozempic for weight loss and bill it as diabetes?
No. Submitting a prescription with an inaccurate diagnosis code is considered fraud. Your doctor must document the actual medical indication for which the drug is prescribed. Medicare claims are audited, and fraudulent billing can result in serious consequences for both patients and providers.
The Bottom Line
Medicare coverage of Ozempic and other GLP-1 drugs depends entirely on why the medication is prescribed. For type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea, Medicare Part D may cover these medications, and the $2,100 annual out-of-pocket cap provides meaningful financial protection.
For weight loss alone, coverage has been prohibited by federal law since 2006. But that is finally changing. The Medicare GLP-1 Bridge starting in July 2026 and the BALANCE Model in 2027 represent the first steps toward broader Medicare coverage of anti-obesity medications.
Medicare drug coverage is complicated, and the rules for GLP-1 medications are evolving rapidly. Working with a knowledgeable Medicare advisor can help you understand your options and find the most cost-effective path to the medications you need.
This article was reviewed by Karl Bruns-Kyler, founder of The Big 65 Medicare Insurance Services and a licensed Medicare insurance advisor with over 20 years of experience, licensed in 33 states.
Last updated: March 2026. Medicare coverage rules and costs are subject to change. Always verify current coverage with your Part D plan or at Medicare.gov.